跳至主要内容
临床试验/ACTRN12612000444886
ACTRN12612000444886已完成未知

Do patients with unilateral sciatica respond differently to the hot and cold temperature sensation compared to pain-free volunteers?

Professor Paul Rolan0 个研究点目标入组 40 人开始时间: 2012年4月18日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • Having both upper and lower limbs present
  • Must be suffering from unilateral sciatica for a minimum of 3 months*
  • Average daily pain score over previous week of more than/equal to 40 on the 100mm VAS scale*
  • In good general health without clinically significant renal, hepatic, cardiac, or other disease, as determined by the Principal Investigator
  • *does not apply to pain-free volunteers
  • Pain-free:
  • Must not have clinically significant pain condition
  • Must not be suffering from any condition or taking any medication which may be associated with neuropathic or central processing (e.g. diabetes)
  • Unilateral sciatica on CHRONIC opioid therapy:
  • Experience pain 5 days/week for at least 3 months
  • Ongoing opioid therapy at a dose equivalent to morphine 20 mg/day for more than 3 months without recent (1 month) dose change
  • Allowed to take non-opioid pain medications without recent (1 month) dose change
  • Unilateral sciatica NOT on opioid therapy:
  • Except codeine less than 30 mg/day
  • Allowed to take non-opioid pain medications without recent (1 month) dose change

排除标准

  • 1.Pregnant or breastfeeding
  • 2.Inadequate veins for blood sampling
  • 3.Significant scarring on the planned site/s of investigation
  • 4.Have an active inflammatory process (e.g. acute pain other than sciatic pain, influenza, active infection, rheumatoid arthritis etc.)
  • 5.Have had a clinically significant infection in the 4 weeks prior to day 1
  • 6.Taking any immunosuppressant drugs e.g. azathioprine, methotrexate, cyclosporine
  • 7.Taking any oral or inhaled corticosteroid medicationsb
  • 8.Sensory deficits at the QST site resulting from medical conditions, such as diabetes; alcoholic neuropathy; severe thyroid, liver or kidney diseases
  • 9.Recent (within 8 weeks prior to day 1) interventional pain management procedures that may alter QST responses including neuraxial or local anaesthetic block to the affected area
  • 10.Recent use of opioids (e.g. morphine use within 1 week, or codeine use (>30mg) within last 5 days)**
  • 11.Change in pain medication dose/type/frequency within 4 weeks of day 1*
  • 12.Use of anxiolytics, anti-depressants and anti-epileptic medications
  • 13.Presence of non-prescribed drugs of abuse in urine drug screen. Enrolment of any participant who returns a positive result will be at the Investigators discretion
  • 14.Suffers from a clinically diagnosed major psychiatric disorder, such as major depression, bipolar disorder, schizophrenia, anxiety disorder, and psychosis
  • 15.A positive breath alcohol concentration (BAC) prior to the testing sessions
  • 16.History of excessive use of alcohol, defined as more than
  • 21 units of alcohol per week for females, and more than 28 units of alcohol per week for males
  • 17.Known history of Hep B, Hep C, or HIV
  • 18.Known disorder of thermal pain sensitivity e.g. Raynaud’s phenomenon
  • 19.Inability to tolerate study procedures at screening familiarisation session
  • * Does not apply to pain-free volunteers.
  • ** Excluding unilateral sciatica participants on opioid therapy

研究者

发起方
Professor Paul Rolan

相似试验